Compromiso pulmonar en el síndrome antifosfolípido

Compromiso pulmonar en el síndrome antifosfolípido

Published 2004-12-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 16 No. 4 (2004): Diciembre
Section
Revisión de tema
How to Cite
Triana Moreno LC. Compromiso pulmonar en el síndrome antifosfolípido .
rev. colomb. neumol. [Internet]. 2004 Dec. 1 [cited 2025 Jun. 7];16(4):236-40. Disponible en: https://doi.org/10.30789/rcneumologia.v16.n4.2004.1091
DOI

https://doi.org/10.30789/rcneumologia.v16.n4.2004.1091
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Luis Carlos Triana Moreno
Hospital Universitario de la Samaritana
    Show authors biography

    Luis Carlos Triana Moreno,

    Internista — Neumólogo. Jefe del Departamento de Urgencias. Hospital Universitario de La Samaritana — Bogotá. Intensivista. UCI Adultos. Hospital Santa Clara — Bogotá.

    El síndrome antifosfolípido o síndrome de Hughes se presenta como la asociación entre estado de hipercoagulabilidad y la presencia de los anticuerpos antifosfolipidos (1- 3). Existen diversos anticuerpos antifosfolipidos que se asocian a los fenómenos trombóticos y a otras manifestaciones clínicas (1,4). El anticoagulante lúpico, los anticuerpos anticardiolipina y los anticuerpos anti B2 glicoproteína |, son los anticuerpos más frecuentemente implicados en el desarrollo de esta entidad (1,3,5).

    El síndrome antifosfolípido puede ocurrir en pacientes con Lupus Eritematoso Sistémico (LES) y algunas otras enfermedades del tejido conectivo, lo que configuraría el síndrome antifosfolípido secundario, también es posible la presencia de los anticuerpos sin ninguna asociación con enfermedades del colágeno, configurando el síndrome antifosfolípido primario (4,6,7). En esta revisión iniciaremos reconociendo las características clínicas y paraclínicas que caracterizan a este síndrome y posteriormente nos concentraremos en el compromiso a nivel pulmonar. 

    Article visits 8 | PDF visits 33

    Downloads

    Download data is not yet available.
    1. Kamashata MA, Hughes GRV. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Op Reumatol 1995; 7: 389-94.
    2. Hughes GRV. The anticardiolipin syndrome.Clin Exp Rheumatol 1985:3.285-6.
    3. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42: 1309-11.
    4. Roubey RAS. Inmunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39:1444-54.
    5. Kamashata MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The manegement of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332. 993-7.
    6. Muñoz-Rodríguez FJ, Font H, Cervera R, Reverter JC, Tassies D, Espinosa G, et al. Clinical study and follow-up of 100 patients with the antphospholipid síndrome. Semin Artritis Rheum 1999; 29:182-90.
    7. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-63.
    8. Brandt JT, Triplett DA, Alving B, Sharrer |. Criteria for de diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74:1185-90.
    9. Ames PRJ. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic erythematosus: a unifiyng 'membrana stress syndrome' hypothesis.Lupus 1994; 371-2.
    10. Vaarala O, Alithan G, Jauhiainem M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction beween antibodies to oxidised low density lipoprotein and to cardiolipin in sistemic lupus erythematosus. Lancet 1993; 341:923-5.
    11. Rand JH, Wu XX, Andree HAM, et al.Pregnancy loss in the antiphospholipid antibody sindrome — a possible thombogenic mechanism.N Engl J Med 1997; 337:1327.
    12. Kmic- Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing
    13. recurrent thrombosis. Arch Intern Med 1997; 157:2101-8.
    14. Merckel PA, Chang YC, Pierangeli SS, Conwery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.Am J Med 1996; 101:576-83.
    15. Lockshin MD. Answers to the antiphospholipid antibody syndrome? N Engl J Med 1995; 332:1025-27.
    16. Devine DV, Bridgen ML. The antiphospholipid syndrome.Postgrad Med 1996; 99:105-22.
    17. Espinosa G, Cervera R, Font J. El pulmón en el síndrome antifosfolipídico. Arch Bronconeumol 2002; 38:27-32.
    18. Hillerdal G. The lung physician and the antiphospholipid syn- drome. Eur Respir J 1997; 10:511-2.
    19. Vianna JL, Kamashata MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid síndrome: a Eu- ropean multicenter study of 114 patients. Am J Med 1994;96:3-9.
    20. Brucato A, Baudo F, Barberis M, Redaelli R, Casadei G, Allegri F, et al. Pulmonary hypertension secondary to thrombosis of the pulmonary vessels in a patient with the primary antiphospholipid syndrome. J Reumatol 1994; 21:942-44.
    21. Ginsberg JS, Wells PS, Brill Edwards P, Donovan D,Moffatt K, Jhonston M, Stevens P, Hirsh J. Antiphospholpid Antibodies and Venous Thromboembolism. Blood 1995; 86:3685-91.
    22. Kunieda T, Nakanishi N, Satoh T, et al.: Prognoses of primary pulmonary hypertension and cronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 1999; 38:543-66.
    23. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000;160:159-64.
    24. Auger WR, Permpikul P, Moser KM, et al. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension. A preliminary report. Am J Med 1995; 99:392-96.
    25. Wolf M, Boyer-Neuman C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000; 15:395-99.
    26. Fedullo P, Auger WR, Channick RN, Kerr KM, Rubin LJ. Chronic Thromboembolic Pulmonary Hypertension. Clinics in Chest Medicine 2001; 22: 561-81.
    27. Atsumi T, Khamashata MA, Haworth RS, Brooks G, Amengual O, Ichikawa K, et al. Arterial disease and thrombosis in the antiphospkolipid syndrome: a pathogenic role of endotelin 1. Arthritis Rheum 1998; 41:800-7.
    28. Ando M, Takamoto S, Okita Y, Matsukawa R, Nakanishi N, Kyotani S, et al. Operation for chronic pulmonary thomboembolism accompanied by thombophilia in 8 patients. Ann Thorac Surg 1998; 66:1919-24.
    29. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Sitbon O, Simmonneau G. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continous IV epoprostenol(prostacyclin). Chest 1998; 114:80-2.
    30. Anderson EN, Ali MR. The lupus anticoagulant, pulmonary thromboembolism and fatal pulmonary hypertension. Ann Rheum Dis 1984; 43:760-3.
    31. Sompraadeekul S, Fedullo PF, Kerr KM, et al. The role pulmonary angioscopy in the preoperative assesssment of patients with thromboembolic pulmonary hypertension(CTEPH). Am J Respir Crit Care Med 1999; 159:A456.
    32. Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM. Fishman's Pulmonary Diseases and Disorders. Tercera edición.Mc Graw Hill; 1998:1193-1210.
    33. Orens J, Martinez FJ, Lynch JP IIl.: Pulmonary Manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20:159-93.
    34. Gertner E. Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment. J Rheumatol 1999; 26:805-7.
    35. Howe HS, Boey ML, Fong KY, Feng PH. Pulmonary hemor- rhage, pulmonary infarction, and thelupus anticoagulant. Ann Rheum Dis 1988; 47:869-72.
    36. Asherson RA, Cervera R, Piette JC, et al. Catasttrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine ( Baltimore) 1998; 77:195-207.
    37. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998;104:381-5.
    38. Kerr JE, Poe R, Kramer Z. Antiphospholipid antiboby syndrome presenting as a refractory noinflammatory pulmonary vasculopathy. Chest 1997; 112:1707-10.
    39. Argento A, DiBenedetto RJ. ARDS and adrenal insufficiency associated with the antiphospholipid antibody sindrome. Chest 1998;113:1136-8.
    40. Wiederman FJ, Mayr A, Schobersberger W, Knotzer H, Sepp N, Rieger M, et al. Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med 2000; 247:723-30.
    41. Savin H, Hoberman M, Kott E, Lishner M, Kitay Y, Kidron D, et al. Fibrosing alveolitis associated with primary antiphospholipid antibodies. J Reumatol 1994; 33: 977-80.
    Tutorials

    Autors:

    How send article?

    Evaluator pair

    How to evaluate an article?

    Information

    Journal history

    Keywords

    Directories and indexes

    Sponsors

    Support + Info Here

     
    Google Scholar profile

    Most read in the last 30 days

    Current Issue

    QR code

    Sistema OJS 3.4.0.7 - Metabiblioteca |